NVAX
$1.59
Novavax
($.03)
(1.85%)
NVAX
Earnings Whisper ®
N/A
2nd Quarter June 2018
Consensus:  ($0.12)
Revenue:  $10.28 Mil
Wednesday
Aug 8
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Wednesday, May 9, 2018

What do you expect when NVAX reports earnings?
Beat
Meet
Miss

Where is NVAX's stock price going from here?
Up
Flat
Down
Stock chart of NVAX
Analysts
Summary of analysts' recommendations for NVAX
Score
Grade
Pivots
Resistance
$1.66
$1.64
$1.62

$1.60

Support
$1.58
$1.56
$1.54
Tweet
Growth
Description
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Peers
BiogenGilead SciencesBluebird BioAmgenSeattle GeneticsNeurocrine BiosciencesQiagen N.V.Bio-TechneRepligenBioCryst Pharmaceuticals